Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has results × Non Small Cell Lung Carcinoma NSCLC × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡